Сytokine expression and production in severe cases of SARS-CoV-2 infection
- Authors: Abramova N.D.1, Meremyanina E.A.1,2, Kalyuzhnaya N.O.1, Poddubikov A.V.1, Kostinov M.P.1,3, Grechenko V.V.4, Svitich O.A.1,3
-
Affiliations:
- I. Mechnikov Research Institute of Vaccines and Sera
- Russian Medical Academy of Continuous Professional Education
- I. Sechenov First Moscow State Medical University (Sechenov University)
- N. Pirogov Russian National Research Medical University
- Issue: Vol 26, No 4 (2023)
- Pages: 603-610
- Section: Forum Sochi 2023
- URL: https://journals.rcsi.science/1028-7221/article/view/253449
- DOI: https://doi.org/10.46235/1028-7221-13957-CEA
- ID: 253449
Cite item
Full Text
Abstract
Most respiratory viral infections proceed in mild form including COVID-19. Gowever, some patients experience severe systemic inflammation, tissue damage, acute respiratory distress syndrome, and cytokine storm with potentially lethal outcomes. The cytokines have been thought to play an important role in immunopathology of viral infection. However, an excessive immune response, manifesting as massive release of pro-inflammatory cytokines, may cause immune damage in the body. Production and release of the cytokines in healthy individuals presumes a significant balance of inflammatory and homeostatic factors. Meanwhile, in the case of COVID-19 disease, uncontrolled increased production of cytokines often occurs with fatal consequences for patients. The aim of this work was to study the level of IL-1β, IL-18 and TNFα gene expression, as well as production of these cytokines at the level of mucous membranes of the upper respiratory tract, in particular in oral cavity, in patients with severe COVID-19 disease.
The present study included patients who recovered from severe COVID-19. The control group consisted of conditionally healthy individuals. Expression levels of the IL-1β, IL-18, and TNFα genes were determined by RT-PCR. The levels of IL-1β, IL-18 and TNFα protein production were determined by multiplex enzyme immunoassay.
The expression levels of IL-1β, IL-18 were reduced at the onset of the disease, as well as in the midpoint of the COVID-19 disease, but increased on the 30th day. The protein production of these cytokines was also reduced in the first days from the onset of the disease. The levels of pro-inflammatory TNFα cytokine was high at the onset of the disease. The level of TNFα production at the onset of the disease was also higher relative to the control group. Subsequently, the TNFα gene expression levels decreased upon progression of the disease.
Thus, the increased expression level of pro-inflammatory cytokines may be explained by the fact that the S protein of the SARS-CoV-2 virus induces increased expression of these cytokines in human monocytes. Meanwhile, appropriate protein levels remain low, especially on day 1 from the onset of the disease. Thus, one may conclude that the virus triggers pyropotosis, however, within 15-30 days from the onset of the disease, when viral replication is already minimal.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalya D. Abramova
I. Mechnikov Research Institute of Vaccines and Sera
Author for correspondence.
Email: and960911@gmail.com
Junior Research Associate, Laboratory of Molecular Immunology, I. Mechnikov Research Institute of Vaccines and Sera
Russian Federation, MoscowE. A. Meremyanina
I. Mechnikov Research Institute of Vaccines and Sera; Russian Medical Academy of Continuous Professional Education
Email: ekaterina@meremianina.ru
PhD (Medicine), Research Associate, Laboratory of Molecular Immunology, I. Mechnikov Research Institute of Vaccines and Sera; Senior Lecturer, Department of Virology, Russian Medical Academy of Continuous Professional Education
Russian Federation, Moscow; MoscowN. O. Kalyuzhnaya
I. Mechnikov Research Institute of Vaccines and Sera
Email: nat_kalyuzhnaya@mail.ru
Junior Research Associate, Laboratory of Molecular Immunology, I. Mechnikov Research Institute of Vaccines and Sera
Russian Federation, MoscowA. V. Poddubikov
I. Mechnikov Research Institute of Vaccines and Sera
Email: poddubikov@yandex.ru
PhD (Biology), Head, Laboratory of Microbiology of Opportunistic Bacteria, I. Mechnikov Research Institute of Vaccines and Sera
Russian Federation, MoscowM. P. Kostinov
I. Mechnikov Research Institute of Vaccines and Sera; I. Sechenov First Moscow State Medical University (Sechenov University)
Email: monolit.96@mail.ru
PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Head, Laboratory of Vaccination and Immunotherapy of Allergic Diseases, I. Mechnikov Research Institute of Vaccines and Sera; Professor, Department of Epidemiology and Modern Technologies of Vaccination, I. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation, Moscow; MoscowV. V. Grechenko
N. Pirogov Russian National Research Medical University
Email: grechenko_v@mail.ru
PhD (Medicine), Associate Professor, Department of Immunology, N. Pirogov Russian National Research Medical University
Russian Federation, MoscowO. A. Svitich
I. Mechnikov Research Institute of Vaccines and Sera; I. Sechenov First Moscow State Medical University (Sechenov University)
Email: svitichoa@yandex.ru
PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Director, I. Mechnikov Research Institute of Vaccines and Sera; Professor, Department of Microbiology, Virology and Immunology, I. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation, Moscow; MoscowReferences
- Василевский И.В. Роль цитокинов при инфекции SARS-CoV-2 и пути блокады цитокинового шторма // Здравоохранение, 2022. № 3. С. 31-41. [Vasilevsky I.V. The role of cytokines in SARS-CoV-2 infection and the cytokine storm blockade. Zdravookhraneniye = Healthcare, 2022, no. 3, pp. 31-41. (In Russ.)]
- Carty M., Guy C., Bowie A.G. Detection of viral infections by innate immunity. Biochem. Pharmacol., 2021, Vol. 183, 114316. doi: 10.1016/j.bcp.2020.114316.
- Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe, 2016, Vol. 19, no 2, pp. 181-193.
- Davidson S., Maini M.K., Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. Interferon Cytokine Res.,, 2015, Vol. 35, no. 4, pp. 252-264.
- Hirano T., Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity, 2020, Vol. 52, no 5, pp. 731-733.
- Hu B., Guo H., Zhou P., Shi Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol., 2021, Vol. 19, no 3, pp. 141-154.
- Maini R.N., Elliott M.J., Brennan F.M., Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin. Exp. Immunol., 1995, Vol. 101, no. 2, pp. 207-212.
- McElvaney O.J., McEvoy N.L., McElvaney O.F., Carroll T.P., Murphy M.P., Dunlea D.M., Ní Choileáin O., Clarke J., O’Connor E., Hogan G., Ryan D., Sulaiman I., Gunaratnam C., Branagan P., O’Brien M.E., Morgan R.K., Costello R.W., Hurley K., Walsh S., de Barra E., McNally C., McConkey S., Boland F., Galvin S., Kiernan F., O’Rourke J., Dwyer R., Power M., Geoghegan P., Larkin C., O’Leary R.A., Freeman J., Gaffney A., Marsh B., Curley G.F., McElvaney N.G. Characterization of the inflammatory response to severe COVID-19 illness. Am. J. Respir. Crit. Care Med., 2020, Vol. 202, no 6, pp. 812-821.
- Pantazi I., Al-Qahtani A.A., Alhamlan F.S., Alothaid H., Matou-Nasri S., Sourvinos G., Vergadi E., Tsatsanis C. SARS-CoV-2/ACE2 Interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages. Front. Immunol., 2021, Vol. 12, 683800. doi: 10.3389/fimmu.2021.683800.
- Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA, 2020, Vol. 324, no. 8, pp. 782-793.
- Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect., 2020, Vol. 80, no 6, pp. 607-613.